Geneos Therapeutics Announces Scientific Meeting Presentation of Sustained Immunosurveillance and Progression-free Survival in Two Brain Cancer Patients Treated with Neoantigen Targeted Personalized DNA Immunotherapy
-- Presentation to be given at the 2026 Society for Neuro-Oncology Annual Meeting will highlight two high grade glioma patients with sustained immunosurveillance in brain cancer offering a promising treatment path -- PHILADELPHIA, Nov. 2, 2026 /PRNewswire/ -- Geneos Therapeutics, a...
Covered in this story
Call it yourself
No calls on $DNA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Ginkgo Bioworks Holdings Inc Class →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.